Recipharm to support formulation and fill-finish a part of Moderna COVID-19 vaccine supply in France facility
Moderna and Recipharm announced that they have reached an agreement to support formulation and fill-finish a part of Moderna’s mRNA COVID-19 vaccine supply outside of the US. The activity will be performed in Recipharm’s drug product manufacturing facility located in France.
Subject to regulatory approval of the vaccine in relevant countries outside of the US, it is anticipated that supply will commence in early 2021.
“We are making important progress in the development of the Moderna COVID-19 vaccine and we are pleased to be entering into this collaboration with Recipharm,” said Nicolas Chornet, Senior Vice President, International Manufacturing, Moderna. “We look forward to their support in the delivery of our vaccine to market.”
“This is a material and strategically important agreement for us, and we are delighted to be working with Moderna on such a vital project to support the long-term fight against COVID-19,” said Thomas Eldered, CEO, Recipharm. “Our preparations are already well underway with the hiring of new staff and investment in the facility to enable us to meet the challenging timelines.”
Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
As a leading Contract Development and Manufacturing Organisation (CDMO), Recipharm operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US.
- Advertisement -